Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Charles D Blanke

Showing results (71-80 of 152) with videos related to

Pageof 16
Sort By:
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancerKaren L Tedesco, Jordan Berlin, Charles D Blanke, et al.
Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer|July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
Cancer|July 22, 2014
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)Cornelia M Ulrich, Cathryn Rankin, Adetunji T Toriola, et al.
Investigational New Drugs|October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Molecular Cancer Therapeutics|August 13, 2009
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumorLori Rink, Yuliya Skorobogatko, Andrew V Kossenkov, et al.
Oncology Reports|June 6, 2007
Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridizationAbbas Agaimy, Antje-Friederike Pelz, Christopher L Corless, et al.
Annals of Surgical Oncology|December 29, 2011
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132Dian Wang, Qiang Zhang, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical TrialsJoseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127Tomislav Dragovich, Sheryl McCoy, Cecilia M Fenoglio-Preiser, et al.
Pageof 16

Showing results (71-80 of 152) with videos related to

Sort By:
Pageof 16
International Journal of Radiation Oncology, Biology, Physics|April 9, 2005
Phase I trial of Orzel (UFT plus leucovorin), cisplatin, and radiotherapy in the treatment of potentially resectable esophageal cancerKaren L Tedesco, Jordan Berlin, Charles D Blanke, et al.
Cancer|April 2, 2015
Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005)Ramesh K Ramanathan, Shannon L McDonough, Hagen F Kennecke, et al.
Cancer|July 22, 2014
Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727)Philip A Philip, Bryan Goldman, Ramesh K Ramanathan, et al.
Cancer|July 22, 2014
Polymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304)Cornelia M Ulrich, Cathryn Rankin, Adetunji T Toriola, et al.
Investigational New Drugs|October 23, 2008
Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)Robert P Whitehead, Cathryn Rankin, Paulo M G Hoff, et al.
Molecular Cancer Therapeutics|August 13, 2009
Gene expression signatures and response to imatinib mesylate in gastrointestinal stromal tumorLori Rink, Yuliya Skorobogatko, Andrew V Kossenkov, et al.
Oncology Reports|June 6, 2007
Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridizationAbbas Agaimy, Antje-Friederike Pelz, Christopher L Corless, et al.
Annals of Surgical Oncology|December 29, 2011
Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132Dian Wang, Qiang Zhang, Charles D Blanke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2022
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical TrialsJoseph M Unger, Riha Vaidya, Kathy S Albain, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 20, 2006
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127Tomislav Dragovich, Sheryl McCoy, Cecilia M Fenoglio-Preiser, et al.
Pageof 16